Sydney Lupkin
Stories
-
The Biden administration is wrapping up negotiations to lower prescription drug prices
The first price negotiations between Medicare and drug companies has been underway since February. What do we know about how it's going?
-
Torrid market for copycat weight loss drugs could be short-lived
Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.
-
Ozempic's popularity leads to shortages for people with Type 2 diabetes
Drugs like Ozempic, Wegovy and Mounjaro are in such high demand that many patients with Type 2 diabetes can't get them when they need them.
-
Health insurers cover fewer drugs and make them harder to get
Insurance companies are covering fewer drugs than they used to, and patients have to jump through more hoops to get many of them. When shopping for insurance, check for coverage of the drugs you need.
-
Insurance covers fewer drugs than in 2010 and they're harder to get
Insurance companies are covering fewer drugs than they did in 2010, and they’re making patients jump through more hoops and pay more money to get them. A report from GoodRx documents the issues.
-
The scientist whose research led to cholesterol-lowering statin drugs, has died.
Akira Endo, the Japanese scientist whose research led to statin drugs, has died. Tens of millions of people in the U.S. take statins to reduce their cholesterol.
-
Thinking of buying Wegovy online. Here’s what to know about compounding pharmacies
As more people try weight-loss drugs like Wegovy, some skip the brand name and buy compounded semaglutide from online pharmacies. But some of these may not follow state and federal standards.
